Smallpox was declared eradicated in 1980. However recently, the need of agents effective against poxvirus infection has emerged again. In this paper, we report an original finding that two redox-modulating agents, the ethacrynic and alpha-lipoic acids (EA, LA), inhibit growth of vaccinia virus (VACV) in vitro. The effect of EA and LA was compared with those of beta-mercaptoethanol, DTT and ascorbic acid, but these agents increased VACV growth in HeLa G cells. The inhibitory effects of EA and LA on the growth of VACV were further confirmed in several cell lines of different embryonic origin, in epithelial cells, fibroblasts, macrophages and T-lymphocytes. Finally, we have analyzed the mechanism of action of the two agents. They both decreased expression of VACV late genes, as demonstrated by western blot analysis and activity of luciferase expressed under control of different VACV promoters. In contrast, they did not inhibit virus entry into the cell, expression of VACV early genes or VACV DNA synthesis. The results suggest new directions in development of drugs effective against poxvirus infection.

Department of Immunology and Microbiology 1st Medical Faculty Charles University of Prague Studnickova 7 128 00 Prague 2 Czech Republic

Zobrazit více v PubMed

Alejo A., Andrés G., Salas M.L. African Swine Fever virus proteinase is essential for core maturation and infectivity. J. Virol. 2003;77:5571–5577. PubMed PMC

Aragon T.J., Ulrich S., Fernyak S., Rutherford G.W. Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963–1968. BMC Public Health. 2003;3:26. PubMed PMC

Arness M.K., Eckart R.E., Love S.S., Atwood J.E., Wells T.S., Engler R.J., Collins L.C., Ludwig S.L., Riddle J.R., Grabenstein J.D., Tornberg D.N. Myopericarditis following smallpox vaccination. Am. J. Epidemiol. 2004;160:642–651. PubMed

Artenstein A.W. New generation smallpox vaccines: a review of preclinical and clinical data. Rev. Med. Virol. 2008;18:217–231. PubMed

Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K., editors. Current Protocols in Molecular Biology. John Wiley & Sons; 2002. p. 650.

Becker M.N., Obraztsova M., Kern E.R., Quenelle D.C., Keith K.A., Prichard M.N., Luo M., Moyer R.W. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol. J. 2008;5:58. PubMed PMC

Bowes T.J., Gupta R.S. Induction of mitochondrial fusion by cysteine-alkylators ethacrynic acid and N-ethylmaleimide. J. Cell. Physiol. 2005;202:796–804. PubMed

Brasier A.R., Tate J.E., Habener J.F. Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. Biotechniques. 1989;7:1116–1122. PubMed

Bray M., Wright M.E. Progressive vaccinia. Clin. Infect. Dis. 2003;36:766–774. PubMed

Byrd C.M., Hruby D.E. Vaccinia virus proteolysis—a review. Rev. Med. Virol. 2006;16:187–202. PubMed PMC

Byrd C.M., Bolken T.C., Hruby D.E. The vaccinia virus I7L gene product is the core protein proteinase. J. Virol. 2002;76:8973–8976. PubMed PMC

De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem. Pharmacol. 2007;73:911–922. PubMed

De Clercq E., Holý A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 2005;4:928–940. PubMed

Gate L., Tew K.D. Glutathione S-transferases as emerging therapeutic targets. Expert Opin. Ther. Targets. 2001;5:477–489. PubMed

Graham S.C., Bahar M.W., Cooray S., Chen R.A., Whalen D.M., Abrescia N.G., Alderton D., Owens R.J., Stuart D.I., Smith G.L., Grimes J.M. Vaccinia virus proteins A52 and B14 share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog. 2008;4:e1000128. PubMed PMC

Greber U.F. Virus assembly and disassembly: the adenovirus cysteine protease as a trigger factor. Rev. Med. Virol. 1998;8:213–222. PubMed

Griffiths N.M., Simmons N.L. Attribution of [3H]bumetanide binding to the Na+K+Cl ‘co-transporter’ in rabbit renal cortical plasma membranes: a caveat. Q. J. Exp. Physiol. 1987;72:313–329. PubMed

Hager K., Kenklies M., McAfoose J., Engel J., Münch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease-a 48 months follow-up analysis. J. Neural Transm. Suppl. 2007;(72):189–193. PubMed

Han Y., Englert J.A., Delude R.L., Fink M.P. Ethacrynic acid inhibits multiple steps in the NF-kappaB signaling pathway. Shock. 2005;23:45–53. PubMed

Holmquist L., Stuchbury G., Berbaum K., Muscat S., Young S., Hager K., Engel J., Münch G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol. Ther. 2007;113:154–164. PubMed

Hruby D.E., Lynn D.L., Kates J.R. Vaccinia virus replication requires active participation of the host cell transcriptional apparatus. Proc. Natl. Acad. Sci. U.S.A. 1979;76:1887–1890. PubMed PMC

Humlová Z., Vokurka M., Esteban M., Melková Z. Vaccinia virus induces apoptosis of infected macrophages. J. Gen. Virol. 2002;83:2821–2832. PubMed

Jariwalla R.J., Lalezari J., Cenko D., Mansour S.E., Kumar A., Gangapurkar B., Nakamura D. Restoration of blood total glutathione status and lymphocyte function following alpha-lipoic acid supplementation in patients with HIV infection. J. Altern. Complement Med. 2008;14:139–146. PubMed

Johnston J.B., Rahman M.M., McFadden G. Strategies that modulate inflammasomes: insights from host-pathogen interactions. Semin. Immunopathol. 2007;29:261–274. PubMed

Joklik W.K. The purification of four strains of poxvirus. Virology. 1962;18:9–18. PubMed

Kaeppler U., Stiefl N., Schiller M., Vicik R., Breuning A., Schmitz W., Rupprecht D., Schmuck C., Baumann K., Ziebuhr J., Schirmeister T. A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. J. Med. Chem. 2005;48:6832–6842. PubMed

Kaiser J. Smallpox vaccine. A tame virus runs amok. Science. 2007;316:1418–1419. PubMed

Karupiah G., Xie Q.W., Buller R.M., Nathan C., Duarte C., MacMicking J.D. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science. 1993;261:1445–1448. PubMed

Kiemer A.K., Müller C., Vollmar A.M. Inhibition of LPS-induced nitric oxide and TNF-alpha production by alpha-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunol. Cell Biol. 2002;80:550–557. PubMed

Koechel D.A., Rankin G.O. Diuretic activity of Mannich base derivatives of ethacrynic acid and certain ethacrynic acid analogues. J. Med. Chem. 1978;21:764–769. PubMed

Krecmerová M., Holý A., Pohl R., Masojidková M., Andrei G., Naesens L., Neyts J., Balzarini J., De Clercq E., Snoeck R. Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. J. Med. Chem. 2007;50:5765–5772. PubMed

Lai C.F., Gong S.C., Esteban M. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J. Virol. 1991;65:5631–5635. PubMed PMC

Lee S.B., Melková Z., Yan W., Williams B.R., Hovanessian A.G., Esteban M. The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells. Virology. 1993;192:380–385. PubMed

Lee S.B., Rodriguez D., Rodriguez J.R., Esteban M. The apoptosis pathway triggered by the interferon-induced protein kinase PKR requires the third basic domain, initiates upstream of Bcl-2, and involves ICE-like proteases. Virology. 1997;231:81–88. PubMed

Ligon B.L. Monkeypox: a review of the history and emergence in the Western hemisphere. Semin. Pediatr. Infect. Dis. 2004;15:280–287. PubMed PMC

Melamed S., Kotas-Neumann R., Barak A., Epstein D.L. The effect of intracamerally injected ethacrynic acid on intraocular pressure in patients with glaucoma. Am. J. Ophthalmol. 1992;113:508–512. PubMed

Melková, Z., 1995. Macrophage antiviral activity: role of IFN gamma and nitric oxide in the inhibition of vaccinia virus growth in macrophages. Thesis, School of Graduate Studies, State University of New York, Health Science Center at Brooklyn.

Melková Z., Esteban M. Interferon-gamma severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology. 1994;198:731–735. PubMed

Melková Z., Esteban M. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J. Immunol. 1995;155:5711–5718. PubMed

Melková Z., Lee S.B., Rodriguez D., Esteban M. Bcl-2 prevents nitric oxide-mediated apoptosis and poly(ADP-ribose) polymerase cleavage. FEBS Lett. 1997;403:273–278. PubMed

Meredith M.J., Reed D.J. Status of the mitochondrial pool of glutathione in the isolated hepatocyte. J. Biol. Chem. 1982;257:3747–3753. PubMed

Merin J.P., Matsuyama M., Kira T., Baba M., Okamoto T. Alpha-lipoic acid blocks HIV-1 LTR-dependent expression of hygromycin resistance in THP-1 stable transformants. FEBS Lett. 1996;394:9–13. PubMed

Ojeda S., Senkevich T.G., Moss B. Entry of vaccinia virus and cell-cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J. Virol. 2006;80:51–61. PubMed PMC

Packer L., Witt E.H., Tritschler H.J. alpha-Lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 1995;19:227–250. PubMed

Pande V., Ramos M.J. Nuclear factor kappa B: a potential target for anti-HIV chemotherapy. Curr. Med. Chem. 2003;10:1603–1615. PubMed

Parker S., Touchette E., Oberle C., Almond M., Robertson A., Trost L.C., Lampert B., Painter G., Buller R.M. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 2008;77:39–49. PubMed PMC

Petersen Shay K., Moreau R.F., Smith E.J., Hagen T.M. Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life. 2008;60:362–367. PubMed

Pirrung M.C., Pansare S.V., Sarma K.D., Keith K.A., Kern E.R. Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents. J. Med. Chem. 2005;48:3045–3050. PubMed

Quenelle D.C., Keith K.A., Kern E.R. In vitro and in vivo evaluation of isatin-[beta]-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiviral Res. 2006;71:24–30. PubMed

Quenelle D.C., Prichard M.N., Keith K.A., Hruby D.E., Jordan R., Painter G.R., Robertson A., Kern E.R. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob. Agents Chemother. 2007;51:4118–4124. PubMed PMC

Reed K.D., Melski J.W., Graham M.B., Regnery R.L., Sotir M.J., Wegner M.V., Kazmierczak J.J., Stratman E.J., Li Y., Fairley J.A., Swain G.R., Olson V.A., Sargent E.K., Kehl S.C., Frace M.A., Kline R., Foldy S.L., Davis J.P., Damon I.K. The detection of monkeypox in humans in the Western hemisphere. N. Engl. J. Med. 2004;350:342–350. PubMed

Rodriguez J.F., Smith G.L. Inducible gene expression from vaccinia virus vectors. Virology. 1990;177:239–250. PubMed

Rodriguez J.F., Rodriguez D., Rodriguez J.R., McGowan E.B., Esteban M. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. U.S.A. 1988;85:1667–1671. PubMed PMC

Rodriguez J.R., Rodriguez D., Esteban M. Insertional inactivation of the vaccinia virus 32-kilodalton gene is associated with attenuation in mice and reduction of viral gene expression in polarized epithelial cells. J. Virol. 1992;66:183–189. PubMed PMC

Safrin S., Cherrington J., Jaffe H.S. Clinical uses of cidofovir. Rev. Med. Virol. 1997;7:145–156. PubMed

Sanford K.K., Earle W.R., Likely G.D. The growth in vitro of single isolated tissue cells. J. Natl. Cancer Inst. 1948;9:229–246. PubMed

Scherer W.F., Syverton J.T., Gey G.O. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J. Exp. Med. 1953;97:695–710. PubMed PMC

Schmidtmayerova H., Alfano M., Nuovo G., Bukrinsky M. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J. Virol. 1998;72:4633–4642. PubMed PMC

Schramm B., Locker J.K. Cytoplasmic organization of poxvirus DNA replication. Traffic. 2005;6:839–846. PubMed

Senkevich T.G., White C.L., Koonin E.V., Moss B. Complete pathway for protein disulfide bond formation encoded by poxviruses. Proc. Natl. Acad. Sci. U.S.A. 2002;99:6667–6672. PubMed PMC

Smee D.F., Sidwell R.W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003;57:41–52. PubMed PMC

Townsley A.C., Senkevich T.G., Moss B. Vaccinia virus A21 virion membrane protein is required for cell entry and fusion. J. Virol. 2005;79:9458–9469. PubMed PMC

Unkeless J.C., Kaplan G., Plutner H., Cohn Z.A. Fc-receptor variants of a mouse macrophage cell line. Proc. Natl. Acad. Sci. U.S.A. 1979;76:1400–1404. PubMed PMC

Vicik R., Busemann M., Baumann K., Schirmeister T. Inhibitors of cysteine proteases. Curr. Top. Med. Chem. 2006;6:331–353. PubMed

White C.L., Senkevich T.G., Moss B. Vaccinia virus G4L glutaredoxin is an essential intermediate of a cytoplasmic disulfide bond pathway required for virion assembly. J. Virol. 2002;76:467–472. PubMed PMC

WHO . vol. 55. WHO; 1980. (Wkly. Epidem. Rep.-Releve Epidem. Hebd). May 16, 1980, 145–152.

Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., De Clercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 2005;79:13139–13149. PubMed PMC

Vaccinia Virus Expressing Interferon Regulatory Factor 3 Induces Higher Protective Immune Responses against Lethal Poxvirus Challenge in Atopic Organism